Articles On Prescient Therapeutics (ASX:PTX)

Title Source Codes Date
Prescient Therapeutics presents new OmniCAR data

Prescient Therapeutics (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in the US.

BiotechDispatch PTX 6 days ago
Prescient has some very positive findings to share about its OmniCAR platform’s tumour-killing abilities

Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting the attention of leading global therapy decision makers. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) will pr...

Stockhead PTX 1 week ago
Prescient Therapeutics unveils new data validating cancer cell therapy technology

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its OmniCAR cell therapy technology in killing multiple cancer cells. The company is presenting this pre-clinical da...

SmallCaps PTX 1 week ago
Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results this week for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California The conference brings together senior executives and decision makers on therapies including cell ther...

themarketherald.com.au PTX 1 week ago
ASX 200 opens higher; Beach Energy, a2 Milk lead gains

Highlights The ASX 200 was up 0.25% or 18.7 points to 7,361.3 at the open. Seven out of the 11 sectors were trading higher with the Metals and Mining sector leading with a 0.3% gain Limeade, Inc received a notice of contract terminati...

Kalkine Media PTX 3 weeks ago
Prescient Therapeutics (ASX:PTX) share price leaps 11%, up 50% in a month

The S&P/ASX 200 index (ASX: XJO) has started the week in the red and is currently down 2% to 7,252.6 points. Whereas the S&P/ASX 200 Health Care index (XHJ) is also around 1% in the red today, one ASX Healthcare share is outpacing...

Motley Fool PTX 1 month ago
Prescient Therapeutics (ASX:PTX) share price up 5% on Thursday

The Prescient Therapeutics Ltd (ASX: PTX) share price has gained a further 5% to trade at 23 cents on Thursday afternoon. Prescient shares have been on the move over this past week and have climbed 28% into the green over this time. What...

Motley Fool PTX 1 month ago
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

Stockhead PTX 1 month ago
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)

Steven Yatomi-Clarke, the CEO & Managing Director of Prescient Therapeutics (PTX), speaks to Peter Switzer.

Switzer PTX 1 month ago
Seven stunning ASX healthcare shares to keep tabs on

Highlights  ASX-listed healthcare companies rarely fail to bring joy to the market participants, with a few of them providing outstanding returns in the last couple of months. Rhinomed, IDT Australia, and Prescient lead the way with ou...

Kalkine Media PTX 1 month ago
A diversified portfolio of cancer treatment medicines

ShareCafeA diversified portfolio of cancer treatment medicines Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers. A diversified portfol...

ShareCafe PTX 1 month ago
Hidden Gems Webinar Recap – BPH, EX1, RAP & PTX

ShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with presentations from BPH Energy (ASX: BPH), Exopharm (ASX: EX1), RessApp (ASX: RAP) & Prescient Therapeutics (ASX: GSS) Hidden Gems Webinar Re...

ShareCafe PTX 1 month ago
Health Kick: Prescient Therapeutics’ YTD share price soars 220% after progress in clinical studies and CAR-T platform

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim interviews Steven Yatomi-Clarke, CEO and managing...

Stockhead PTX 2 months ago
Prescient announces key hire as leading US neurosurgeon Donald M O’Rourke joins its Advisory Board

The appointment gives PTX a world-leading development team in the race to find solutions for next-generation CAR-T cancer therapies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced a major new staff hire this...

Stockhead PTX 2 months ago
Prescient Therapeutics appoints leading brain cancer specialist to advisory board

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to its scientific advisory board. Professor O’Rourke has considerable expertise in glioblastoma multiforme (GB...

SmallCaps PTX 2 months ago
90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)

Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted ther...

Stockhead PTX 2 months ago
After ‘tremendous’ FY 2021, Prescient Therapeutics well-funded to advance cancer-fighting therapies

Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple cancer programs, with work to follow on from what managing director Steven Yatomi-Clarke describes as “tremendous...

SmallCaps PTX 2 months ago
Why the Prescient (ASX:PTX) share price is surging 8% today

The Prescient Therapeutics Ltd (ASX: PTX) share price is off to the races, up 8% to 19.5 cents in early afternoon trade. Prescient is a clinical-stage oncology company focused on developing personalised treatments for cancer. Below, we tak...

Motley Fool PTX 2 months ago
‘Very encouraging’: Two cancer patients see partial remission and long-lasting benefits after treatment with Prescient’s PTX-100

Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an early clinical trial – and seemed to benefit two patients with aggressive, hard-to-treat lymphoma. Prescient says it is encoura...

Stockhead PTX 2 months ago
Prescient Therapeutics (ASX:PTX) share price flat after trial success news

The Prescient Therapeutics Ltd (ASX: PTX) share price is having a lacklustre day, despite a positive readout on its PTX-100 trial. Prescient shares dipped into the red in morning trade. However, at the time of writing they are exchanging...

Motley Fool PTX 2 months ago
The Prescient (ASX: PTX) share price is surging 12%. Here’s why

The Prescient Therapeutics Ltd (ASX: PTX) share price is soaring today, despite the company not releasing any news. The last time we heard price-sensitive news from the biotechnology company was on 5 July. Right now, the Prescient Therapeu...

Motley Fool PTX 2 months ago
The Prescient (ASX:PTX) share price rocketed 10% higher today. Here’s why

Shares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of news its cancer treatment drug, OmniCAR, has been substantially de-risked. After reaching a multi-year high of 26.5 cents this morning, the...

Motley Fool PTX 3 months ago
Prescient shares rip higher as immunogenicity testing results for OmniCAR ‘could not have been better’

The results significantly de-risk the project as PTX continues development of its OmniCAR platform.  As it builds out its OmniCAR cancer treatment platform, clinical stage oncology company Prescient Therapeutics (ASX:PTX) has updated invest...

Stockhead PTX 3 months ago
Market Highlights and 5 ASX Small Caps to watch on Monday

Wall Street at fresh record highs All three major US benchmarks closed on Friday at new record highs, with intraday gains led by the tech-focused Nasdaq which was 0.81%. US stocks were bolstered by monthly jobs data which showed the unemplo...

Stockhead PTX 3 months ago
Safety in mind as Prescient Therapeutics develops next-generation CAR-T platform

Tragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy after the deaths of two patients, a sobering reminder of the dangers involved in cell therapy. The patients reportedly died from immune effector...

Stockhead PTX 3 months ago
ScoPo’s Powerplays: Buying opportunities in a volatile week and stock downgrades

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Stockhead PTX 3 months ago
Prescient equips CAR-T cells with cancer-fighting binders in manufacturing milestone

The company will now proceed to its next phase of research at the world-leading Peter Mac cancer research centre. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced another crucial step forward in the development...

Stockhead PTX 3 months ago
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Stockhead PTX 4 months ago
Invion led a group of ASX cancer stocks up after promising news

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead PTX 4 months ago
Prescient signs CAR-T agreement with Peter Mac Cancer Centre

Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising the OmniCAR platform.

BiotechDispatch PTX 5 months ago
Prescient Therapeutics signs CAR-T agreement with Peter Mac Cancer Centre

The new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research program with Peter Mac into Cell Therapy Enhancements.

Proactive Investors PTX 5 months ago
Prescient strengthens ties with leading CAR-T research centre

The deal provides the ideal platform for Prescient to develop its OmniCAR product suite as part of broader CAR-T cancer treatment pathways. Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this m...

Stockhead PTX 5 months ago
Quarterlies Top 6: Who got a standing ovation today?

With the number of days left to file March quarterly reports running a little short this month, it is no surprise that the ASX has been flooded with companies racing to beat the deadline. We begin this roundup with Marenica Energy (ASX:MEY)...

Stockhead PTX 5 months ago
Market highlights and 5 ASX small caps to watch on Friday

Wall Street wobbles on tax hike All three major indices in the US fell overnight, after a report saying that the Biden administration may increase the capital gains tax on wealthy individuals. The Dow Jones fell 0.94%, the S&P500 was do...

Stockhead PTX 5 months ago
Prescient Therapeutics Ltd - Prescient Therapeutics (PTX:ASX) Reports Quarterly Results and Operating Highlights

Our summary of Prescient Therapeutics Ltd's recent announcement What has happened? Prescient Therapeutics (PTX:ASX) announced their second-quarter activities and cashflow report which covered their financials, the PTX-100 and PTX-200 clinic...

SmallCapInsider PTX 8 months ago
Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform

Special Report: Australian biotech company Prescient Therapeutics (ASX:PTX) has announced what’s next for its next-generation gene therapy technology for fighting ... Read More The post Prescient Therapeutics chooses three cancer programs f...

Stockhead PTX 9 months ago
Prescient Therapeutics (ASX:PTX) initiates Three Internal OmniCAR Programs

Summary Prescient Therapeutics announced three internal development programs related to unique OmniCAR capabilities. Each of the OmniCAR development programs signifies a considerable market opportunity for the oncology company. Presci...

Kalkine Media PTX 9 months ago
Prescient Therapeutics Ltd - Prescient Therapeutics (PTX:ASX) Announces Three Internal OmniCAR Programs for Next-Gen CAR-T Therapies

Our summary of Prescient Therapeutics Ltd's recent announcement What's happened? Prescient Therapeutics (ASX:PTX) today announced three new internal development programs for OmniCAR, it's next-generation CAR-T cancer therapy platform, whic...

SmallCapInsider PTX 9 months ago
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)

Prescient Therapeutics CEO Steven Yatomi-Clarke speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

Switzer PTX 9 months ago
Prescient Therapeutics (ASX:PTX) Appoints Globally Renowned Haematologist to Scientific Advisory Board

Summary Prescient Therapeutics has appointed Professor H. Miles Prince to its Scientific Advisory Board. Professor Prince holds significant experience in several other areas of cancer therapies and drug development. He has pioneered t...

Kalkine Media PTX 10 months ago
A year of transformation and continuing to forge ahead: Prescient Therapeutics ticks all right boxes in 2020

Summary Last 12 months have been fruitful for Prescient Therapeutics despite the challenges and uncertainties amid the COVID-19. The Company achieved its objectives for targeted as well as cell therapies during the period. A truly tra...

Kalkine Media PTX 10 months ago
Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

Summary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100. It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treat...

Kalkine Media PTX 11 months ago
Scan Through Prescient Therapeutics’ (ASX:PTX) Most Significant September 2020 Quarterly Results

Summary Prescient ended the September 2020 quarter with a cash balance of almost A$18.6 million following the successful capital raising in August 2020. During the quarter, two assets of PTX were selected for priority antiviral COVID-19...

Kalkine Media PTX 11 months ago
Shedding Light on Prescient Therapeutics’ (PTX) Personalised Cancer Treatments

Summary Supported by an international leadership team with extensive expertise in cancer therapy, Prescient has developed a robust product pipeline, comprising personalised cancer treatments. Prescient’s drug pipeline comprises CAR-T an...

Kalkine Media PTX 1 year ago
Prescient Therapeutics completes successful placement

Prescient Therapeutics (ASX:PTX) has announced that it has received commitments to raise over $7 million before costs by way of a share placement to professional and sophisticated investors.

BiotechDispatch PTX 1 year ago
PTX Solidifies Balance Sheet Further: Announces A$7 million Placement to Support Expanded Pipeline of Innovative Cancer Therapies

On 26 August 2020, Prescient Therapeutics Limited (ASX:PTX) announced that it has received firm commitments to raise A$7,046,084 (before costs) by way of a share placement of 128,110,611 fully paid ordinary shares to professional as well as...

Kalkine Media PTX 1 year ago
Sophisticated and professional investors line up to give Prescient Therapeutics cash

Special Report: Prescient Therapeutics has boosted its cash balance to $20.3m, leaving it well funded to research targeted personalised CAR-T cancer treatments following a successful $13.5m capital raising. Prescient Therapeutics (ASX:PTX)...

Stockhead PTX 1 year ago
Prescient Therapeutics raises $7 million to fund cancer treatment pipeline

Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The clinical stage oncology company today announced it has received firm commitments from professiona...

SmallCaps PTX 1 year ago
Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing direct...

Stockhead PTX 1 year ago
Prescient Therapeutics – ShareCafe Hidden Gems Webinar Presentation

ShareCafePrescient Therapeutics – ShareCafe Hidden Gems Webinar Presentation   Presenter – Steven Yatomi-Clarke – CEO & MD – Prescient is focused on developing novel, personalised therapies against a range of cancers. Prescient’s unive...

ShareCafe PTX 1 year ago